Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Gap 19 is a nonapeptide derivative of connexin43 (Cx43) and an inhibitor of Cx43 hemichannels.1,2 It suppresses the membrane charge transfer (Qm) in HeLa cells expressing Cx43 (IC50 = ~6.5 µM), as well as Cx43 hemichannel currents in isolated guinea pig cardiomyocytes when used at a concentration of 100 µM.1 Gap 19 inhibits glutamate-induced ATP release, a marker of Cx43 hemichannel activity, in primary mouse astrocytes.2 In vivo, Gap 19 (300 µg/kg, i.c.v.) decreases cortical neuronal loss, infarct volume, and the number of errors in a foot fault test in a mouse model of cerebral ischemia and reperfusion injury induced by middle cerebral artery occlusion (MCAO).3 It also reduces infarct size in a mouse model of myocardial ischemia and reperfusion injury induced by ligation of the left anterior descending (LAD) artery when administered at a dose of 25 mg/kg.1
WARNING This product is not for human or veterinary use.
1. Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury. Basic Res. Cardiol. 108(1), 309 (2013).
2. The connexin43 mimetic peptide Gap19 inhibits hemichannels without altering gap junctional communication in astrocytes. Front. Cell Neurosci. 8, 306 (2014).
3. Inhibition of Connexin43 hemichannels with Gap19 protects cerebral ischemia/reperfusion injury via the JAK2/STAT3 pathway in mice. Brain Res. Bull. 146, 124-135 (2019).